Biocatalysis has evolved from a scientific curiosity into a powerful manufacturing platform, culminating in enlicitide, the first oral macrocyclic peptide PCSK9 inhibitor. Merck’s David Thaisrivongs explains how enzyme engineering helped create this “Goldilocks” class of medicines—and could open previously inaccessible drug targets to oral therapies.
Produced and hosted by Jonathan D. Grinstein, PhD
Audio mixed and mastered by Erick Ziegler
Brought to you by Inside Precision Medicine (SAGE Publishing)
","author_name":"Inside Precision Medicine"}